Wonder Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-06-2024
- Paid Up Capital ₹ 3.00 M
as on 16-06-2024
- Company Age 6 Year, 15 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.48 Cr
as on 16-06-2024
- Revenue 68.24%
(FY 2023)
- Profit 92.06%
(FY 2023)
- Ebitda 189.18%
(FY 2023)
- Net Worth 51.11%
(FY 2023)
- Total Assets 0.16%
(FY 2023)
About Wonder Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹1.48 Cr.
Bidisha Bhattacharjee and Himadri Bhattacharjee serve as directors at the Company.
- CIN/LLPIN
U51909WB2019PTC229668
- Company No.
229668
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jan 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Wonder Drugs Private Limited offer?
Wonder Drugs Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Cream, Ointment & Powder, Child and Baby Care Products, Baby Care Products, Pain Relief Drugs & Pharmaceuticals, Pain Reliever Gel, Common Disease Medicines, Hair Growth Medicine, Digestive System Drugs & Medicines, Antacid Drugs.
Who are the key members and board of directors at Wonder Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bidisha Bhattacharjee  | Whole-Time Director | 08-Jan-2019 | Current |
| Himadri Bhattacharjee | Whole-Time Director | 08-Jan-2019 | Current |
Financial Performance of Wonder Drugs.
Wonder Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 68.24% increase. The company also saw a substantial improvement in profitability, with a 92.06% increase in profit. The company's net worth Soared by an impressive increase of 51.11%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wonder Drugs?
In 2023, Wonder Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 27 Jun 2023 | ₹1.35 Cr | Open |
Hdfc Bank Limited Creation Date: 29 Jul 2022 | ₹1.27 M | Open |
How Many Employees Work at Wonder Drugs?
Unlock and access historical data on people associated with Wonder Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wonder Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wonder Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.